JPWO2023051621A5 - - Google Patents
Info
- Publication number
- JPWO2023051621A5 JPWO2023051621A5 JP2024519329A JP2024519329A JPWO2023051621A5 JP WO2023051621 A5 JPWO2023051621 A5 JP WO2023051621A5 JP 2024519329 A JP2024519329 A JP 2024519329A JP 2024519329 A JP2024519329 A JP 2024519329A JP WO2023051621 A5 JPWO2023051621 A5 JP WO2023051621A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- antigen
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111149114 | 2021-09-29 | ||
| CN202111149114.9 | 2021-09-29 | ||
| PCT/CN2022/122185 WO2023051621A1 (zh) | 2021-09-29 | 2022-09-28 | 抗lag3抗体、药物组合物及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536881A JP2024536881A (ja) | 2024-10-08 |
| JPWO2023051621A5 true JPWO2023051621A5 (enExample) | 2025-10-03 |
Family
ID=85770153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519329A Pending JP2024536881A (ja) | 2021-09-29 | 2022-09-28 | 抗ｌａｇ３抗体、医薬組成物、及び使用 |
| JP2024520079A Pending JP2024538669A (ja) | 2021-09-29 | 2022-09-29 | 抗ｌａｇ３二重特異性抗体、医薬組成物、及び使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520079A Pending JP2024538669A (ja) | 2021-09-29 | 2022-09-29 | 抗ｌａｇ３二重特異性抗体、医薬組成物、及び使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20250042995A1 (enExample) |
| EP (2) | EP4410835A4 (enExample) |
| JP (2) | JP2024536881A (enExample) |
| KR (2) | KR20240083095A (enExample) |
| CN (2) | CN115873116A (enExample) |
| AU (2) | AU2022355381A1 (enExample) |
| CA (2) | CA3233205A1 (enExample) |
| IL (2) | IL311738A (enExample) |
| MX (2) | MX2024003936A (enExample) |
| WO (2) | WO2023051621A1 (enExample) |
| ZA (2) | ZA202403273B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022550211A1 (en) * | 2019-08-02 | 2022-12-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anti-pd-1 antibody and medical use thereof |
| WO2023051621A1 (zh) * | 2021-09-29 | 2023-04-06 | 中山康方生物医药有限公司 | 抗lag3抗体、药物组合物及用途 |
| CN119971023A (zh) * | 2023-11-02 | 2025-05-13 | 正大天晴(广州)医药有限公司 | 含抗lag-3抗体的药物组合物及其用途 |
| CN120714022A (zh) * | 2024-03-27 | 2025-09-30 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
| CN120919303A (zh) * | 2024-05-10 | 2025-11-11 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
| CN120518768A (zh) * | 2025-05-30 | 2025-08-22 | 中国人民解放军军事科学院军事医学研究院 | 抗lag-3的单克隆抗体、抗pd-1与lag-3的双特异性抗体、制备方法及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| US10081681B2 (en) * | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| SI3556775T1 (sl) | 2014-01-28 | 2022-02-28 | Bristol-Myers Squibb Company | Protitelesa proti-LAG-3 za zdravljenje hematoloških malignosti |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN106632674B (zh) | 2015-10-30 | 2018-11-16 | 泽达生物医药有限公司 | 一种抗pd-1单克隆抗体、其药物组合物及其用途 |
| MX2018007406A (es) * | 2015-12-16 | 2018-08-15 | Merck Sharp & Dohme | Anticuerpos anti-lag3 y fragmentos de enlace al antigeno. |
| IL263542B2 (en) * | 2016-06-14 | 2024-10-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
| US11214618B2 (en) * | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN116375876A (zh) * | 2017-04-05 | 2023-07-04 | 豪夫迈·罗氏有限公司 | 特异性结合pd1和lag3的双特异性抗体 |
| US20200079850A1 (en) * | 2017-05-24 | 2020-03-12 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| HUE065242T2 (hu) * | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| BR112020011664A2 (pt) * | 2017-12-22 | 2020-11-17 | Jiangsu Hengrui Medicine Co., Ltd. | composição farmacêutica do anticorpo lag-3 e seu uso |
| WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| CN110615840A (zh) * | 2018-06-19 | 2019-12-27 | 信达生物制药(苏州)有限公司 | 全人源的抗lag-3抗体及其应用 |
| WO2020038397A1 (en) * | 2018-08-21 | 2020-02-27 | I-Mab | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof |
| CN115340606B (zh) * | 2019-05-31 | 2023-12-19 | 瑞阳(苏州)生物科技有限公司 | 与人lag-3蛋白结合的抗体及其编码基因和应用 |
| CN112079925B (zh) * | 2019-06-13 | 2025-04-25 | 上海健信生物医药科技有限公司 | 靶向lag-3的抗体和双特异性抗体及其用途 |
| KR20220070201A (ko) * | 2019-09-30 | 2022-05-30 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 항-pd-1 항체 및 이의 용도 |
| CA3162748A1 (en) * | 2019-11-25 | 2021-06-03 | Akeso Biopharma, Inc. | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof |
| WO2021133653A1 (en) * | 2019-12-23 | 2021-07-01 | Macrogenics, Inc. | Therapy for the treatment of cancer |
| CN113348182B (zh) * | 2019-12-30 | 2022-07-12 | 上海海路生物技术有限公司 | Lag-3抗体及其医药用途 |
| KR20220131279A (ko) * | 2020-01-21 | 2022-09-27 | 상하이 헨리우스 바이오테크, 인크. | 항lag3단일 클론 항체 및 그 제조 방법과 응용 |
| WO2022188867A1 (zh) * | 2021-03-12 | 2022-09-15 | 中山康方生物医药有限公司 | 提高含有免疫球蛋白Fc片段的药物的安全性的方法 |
| WO2023051621A1 (zh) * | 2021-09-29 | 2023-04-06 | 中山康方生物医药有限公司 | 抗lag3抗体、药物组合物及用途 |
-
2022
- 2022-09-28 WO PCT/CN2022/122185 patent/WO2023051621A1/zh not_active Ceased
- 2022-09-28 CN CN202211192782.4A patent/CN115873116A/zh active Pending
- 2022-09-28 CA CA3233205A patent/CA3233205A1/en active Pending
- 2022-09-28 KR KR1020247012890A patent/KR20240083095A/ko active Pending
- 2022-09-28 IL IL311738A patent/IL311738A/en unknown
- 2022-09-28 AU AU2022355381A patent/AU2022355381A1/en active Pending
- 2022-09-28 US US18/696,559 patent/US20250042995A1/en active Pending
- 2022-09-28 EP EP22875004.8A patent/EP4410835A4/en active Pending
- 2022-09-28 MX MX2024003936A patent/MX2024003936A/es unknown
- 2022-09-28 JP JP2024519329A patent/JP2024536881A/ja active Pending
- 2022-09-29 CN CN202211199026.4A patent/CN115873123A/zh active Pending
- 2022-09-29 CA CA3233192A patent/CA3233192A1/en active Pending
- 2022-09-29 EP EP22875065.9A patent/EP4410837A4/en active Pending
- 2022-09-29 MX MX2024003935A patent/MX2024003935A/es unknown
- 2022-09-29 JP JP2024520079A patent/JP2024538669A/ja active Pending
- 2022-09-29 US US18/696,546 patent/US20240392040A1/en active Pending
- 2022-09-29 WO PCT/CN2022/122556 patent/WO2023051683A1/zh not_active Ceased
- 2022-09-29 AU AU2022355986A patent/AU2022355986A1/en active Pending
- 2022-09-29 KR KR1020247014429A patent/KR20240083096A/ko active Pending
- 2022-09-29 IL IL311692A patent/IL311692A/en unknown
-
2024
- 2024-04-26 ZA ZA2024/03273A patent/ZA202403273B/en unknown
- 2024-04-26 ZA ZA2024/03275A patent/ZA202403275B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7606257B2 (ja) | 抗ｃｄ２７６抗体、抗体薬物複合体、及びその使用 | |
| CN113710271A (zh) | 抗cd228抗体和抗体-药物缀合物 | |
| WO2023102875A1 (en) | Anti-cdh6 antibody drug conjugate | |
| WO2023143365A1 (zh) | Her3抗体药物偶联物及其用途 | |
| JP2025520772A (ja) | 抗ｅｇｆｒ／ｍｅｔ抗体及びその使用 | |
| JPWO2023051621A5 (enExample) | ||
| CN105828841A (zh) | 抗-efna4抗体-药物缀合物 | |
| KR20240135654A (ko) | 항-her2/trop2 항체 및 이의 용도 | |
| JPWO2022087243A5 (enExample) | ||
| CN118786146A (zh) | 一种抗体及其药物偶联物和用途 | |
| JPWO2022042719A5 (enExample) | ||
| JPWO2023051683A5 (enExample) | ||
| WO2024051762A1 (en) | Anti-trop2/egfr antibodies and uses thereof | |
| TW202508637A (zh) | 修飾的抗體、其抗體片段和抗體藥物偶聯物 | |
| JPWO2022147532A5 (enExample) | ||
| RU2024109579A (ru) | Анти-LAG3 антитело, фармацевтическая композиция и применение | |
| JPWO2022188832A5 (enExample) | ||
| WO2025131054A1 (en) | Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof | |
| JP7594708B1 (ja) | ネクチン４を標的としエキサテカンペイロードを含む抗体薬物コンジュゲート（ａｄｃ） | |
| RU2025127006A (ru) | Анти-lag3 антитело, фармацевтическая композиция и применение | |
| WO2025140662A1 (en) | Anti-egfr/her3 antibodies and uses thereof | |
| WO2024149195A1 (en) | Anti-egfr/muc1 antibodies and uses thereof | |
| RU2025129716A (ru) | Биспецифическое антитело, фармацевтическая композиция и применение | |
| WO2025067306A1 (zh) | 靶向her3的抗体-药物偶联物 | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof |